Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2

Cancer Immunology Immunotherapy

Volumn 42, Issue 2, 1996, Pages 88-92

  Pancook, James D ^a   Becker, Jürgen C ^a   Gillies, Stephen D ^b   Reisfeld, Ralph A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Fuji ImmunoPharmaceuticals Corp   (United States)

Author keywords

Antibody IL 2 fusion protein; Neuroblastoma metastases

Indexed keywords

GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; HYBRID PROTEIN; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOTHERAPY; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; LIVER METASTASIS; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-2; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030007139     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050256     Document Type: Article

References (23)

1. Foon KA (1989) Biological response modifiers: the new immunotherapy. Cancer Res 49: 1621-1639
2. George AJT, Spooner RA, Epenetos AA (1994) Applications of monoclonal antibodies in clinical oncology. Immunol Today 15: 559-561
3. Goldenberg DM, Larson SM, Reisfeld RA, Schlom J (1995) Targeting cancer with radiolabeled antibodies. Immunol Today 16: 261-264
4. Ghetie M-A, Vitetta ES (1994) Recent developments in immunotoxin therapy. Curr Opin immunol 6: 707-714
5. Handgretinger R, Baader P, Dopfer R, Klingbiel T, Reuland P, Reisfeld RA, Treuner J, Niethammer D (1992) A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14G2a. Cancer Immunol Immunother 35: 199-204
6. Handgretinger R, Anderson K, Lang P, Dopfer R, Klingbiel T, Schrappe M, Reuland P, Gillies SD, Reisfeld RA, Niethammer D (1995) A phase I study of human/mouse chimeric anti-ganglioside GD2 antibody ch14,18 in patients with neuroblastoma. Eur J Cancer 31A: 261-267
7. Jurcic JG, Scheinberg DA (1994) Recent developments in the radioimmunotherapy of cancer. Curr Opin Immunol 6: 715-721
8. Maas RA, Dullens HFJ, Otter WD (1993) IL2 in cancer treatment. Cancer Immunol Immunother 36: 141-148
9. Goldsmith MA, Greene WC (1994) Interleukin-2 ant the interleukin-2 receptor. In: Thomson (ed) The cytokine handbook. Harcourt Brace & Company, London, vol 2. pp 57-80
10. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high dose interleukin 2 in the treatment of 652 cancer patients. Ann Surg 210: 474-485
11. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentraber DS, Weber JS, Parkinson DR, Seipp CA, Einhorn JD, White DE (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 86: 1159-1166
12. Dummer R, Gore ME, Hancock BW, Guillou PJ, Grobben HC, Becker JC, Oskam R, Dieleman JP, Burg G (1995) A multicenter phase II clinical trial using dacarbazine and continous infusion of IL2 for metastatic melanoma. Cancer 75: 1038-1044
13. Colombo MP, Forni G (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15: 48-51
14. Maass G, Schmidt W, Berger M, Schilcher F, Koszik F, Schneeberger A, Stingl G, Birnstiel ML, Schweighoffer T (1995) Priming of tumor specific T cells in the draining lymph nodes after immunization with IL2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 92: 5540-5544
15. Schmidt-Wolf G, Schmidt-Wolf IGH (1995) Cytokines and clinical gene therapy. Eur J Immunol 25: 1137-1140
16. Fell HP, Gayle MA, Grosmaire L, Ledbetter JA (1991) Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab′) with specificity for carcinomas and human IL2. J Immunol 146: 2446-2452
17. Gillies SD, Reilly EB, Lo K-M, Reisfeld RA (1992) Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA 89: 1428-1432
18. Savage P, So A, Spooner RA, Epenetos AA (1993) A recombinant single chain antibody interleukin-2 fusion protein. Br J Cancer 67: 304-310
19. Gillies SD, Young D, Lo K-M, Roberts S (1993) Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjugate Chem 4: 230-235
20. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA (1994) A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodefficiency mice. Proc Natl Acad Sci USA 91: 9626-9630
21. Takahashi H, Nakada T, Puisieus I (1993) Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 259: 1460-1463
22. Hank JA, Surtus J, Gan J, Cheu-T-L, Hong R, Tans K, Reisfeld RA, Seeges RC, Reynolds GP, Bauer M, Wiersma S, Hammond D, Scudel PM (1994) Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 15: 29-37
23. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM (1994) Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells. Immunol Lett 39: 91-99